...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Top-line vs. Full Detailed Clinical Trial Results

I forgot to mention that along with the full clinical trial results for EMPA-REG OUTCOME being presented at EASD 2015, the full trial data was simultaneously published in the New England Journal of Medicine. EMPA-REG OUTCOME acheived a hazard ratio of 0.86 translating to a relative risk reduction of 14%. 

BearDownAZ

Share
New Message
Please login to post a reply